The power to save the planet is inside us all – how to get past despair to powerful action on climate change
Our species is in a race with climate change, and a lot of people want to know, 'Can I really make a difference?'
The question concerns what's known as agency. Its meaning is complex, but in a nutshell it means being able to do what you set out to do and believing you can succeed.
How well people exercise their agency will determine the severity of global warming – and its consequences.
The evidence is clear that people are changing the climate dramatically. But human actions can also affect the climate for the better by reducing fossil fuel burning and carbon emissions. It's not too late to avert the worst effects of climate change, but time is running out.
Despite abundant technical agency, humanity is alarmingly short of psychological agency: belief in one's personal ability to help. A 10-country survey study in the Lancet, a British medical journal, found that more than half of young people ages 16-25 feel afraid, sad, anxious, angry, powerless and helpless about climate change.
As professors, we bring complementary perspectives to the challenges of taking action on climate change. Tom Bateman studies psychology and leadership, and Michael Mann is a climate scientist and author of the 2022 book 'The New Climate War.'
Human activities – particularly relying on coal, oil and natural gas for energy – have dramatically affected the climate, with dire consequences.
As greenhouse gases from burning fossil fuel use accumulate in the atmosphere, they warm the planet. Rising global temperatures have fueled worsening heat waves, rising sea levels and more intense storms that become increasingly harder to adapt to. A new report from the Intergovernmental Panel on Climate Change describes some of the dangerous disruptions already underway, and how they are putting people and the environment at risk.
Just like humans can choose to drive gas-guzzlers, they can also choose to act in ways that influence the climate, air quality and public health for the better. Scientific knowledge and countless opportunities for action make that agency possible.
A key part of agency is one's belief, when faced with a task to perform, a situation to manage, or a long-term goal like protecting the climate, that 'I can do this.' It's known as self-efficacy.
This may be the most important psychological factor in predicting how well people will cope with both climate change and COVID-19, recent online survey data from Europe indicate. People feeling adequate agency are more likely to persevere, rebound from setbacks and perform at high levels.
With climate change, a high sense of self-efficacy strengthens a person's willingness to reduce carbon emissions (mitigation) and prepare for climate-related disasters (adaptation). Studies confirm this for actions including volunteering, donating, contacting elected officials, saving energy, conserving water during extreme weather, and more.
To build agency for something that can feel as daunting as climate change, focus first on the facts. In the case of climate change: Greenhouse gas emissions cause the most harm, and people can help far more than they realize.
Successful agency has four psychological drivers, all of which can be strengthened with practice:
1) Intentionality: 'I choose my climate goals and actions for high impact.'
Deciding to act with purpose—knowing what you intend to do–is far more effective than thinking 'My heart's in the right place, I just have to find the time.'
In the big picture, one's highest climate efficacy is in participating in larger efforts to stop fossil fuel use. People can set specific ambitious goals for reducing personal and household energy use and join others in collective actions.
2) Forethought: 'I am looking ahead and thinking strategically about how to proceed.'
Knowing your goals, you can think strategically and develop an action plan. Some plans support relatively simple goals involving individual lifestyle changes, such as adjusting consumption and travel patterns. Wider reaching actions can help change systems – such as long-term activities that advocate for climate-friendly policies and politicians, or against policies that are harmful. These include demonstrations and voter campaigns.
3) Self-regulation: 'I can manage myself over time to optimize my efforts and effectiveness.'
Worrying about the future is becoming a lifelong task—off and on for some, constant for others. Climate change will cause disasters and scarcities, disrupt lives and careers, heighten stress and harm public health. Seeing progress and working with others can help relieve stress.
4) Self-reflection: ' I will periodically assess my effectiveness, rethink strategies and tactics, and make necessary adjustments.'
It's difficult to imagine a greater need for lifelong learning than as we navigate decades of climate change, its many harms and efforts by fossil fuel companies to obscure the facts. Reflection – or, more precisely, keeping up with the latest science, learning and adapting – is vital as the future keeps presenting new challenges.
Even seemingly minor first steps can help reduce carbon emissions and lead to paths of greater action, but individual actions are only part of the solution. Big polluters often urge consumers to take small personal actions, which can deflect attention from the need for large-scale policy interventions.
Individual agency should be seen as a gateway for group efforts that can more quickly and effectively change the trajectory of climate change.
'Collective agency' is another form of agency. A critical mass of people can create societal [tipping points] that pressure industry and policymakers to move more quickly, safely and equitably to implement policies that reduce greenhouse gas emissions.
Helping to elect local, state and national officials who support protecting the climate, and influencing investors and leaders of corporations and associations, can also create a sense of agency, known as 'proxy agency.'
[Over 150,000 readers rely on The Conversation's newsletters to understand the world. Sign up today.]
Together, these efforts can rapidly improve humanity's capacity to solve problems and head off disasters. Fixing the world's climate mess requires both urgency and a sense of agency to create the best possible future.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Thomas S. Bateman, University of Virginia and Michael E Mann, Penn State
Read more:
7 ways to get proactive about climate change instead of feeling helpless: Lessons from a leadership expert
A mild-mannered biker triggered a huge debate over humans' role in climate change – in the early 20th century
Pew's new global survey of climate change attitudes finds promising trends but deep divides
Michael E Mann receives grant funding for climate research from the National Science Foundation, Department of Energy, National Oceanographic and Atmospheric Administration
Thomas S. Bateman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

an hour ago
NIH scientists sign open letter criticizing Trump administration's grant cancellations, firings
More than 300 scientists from the National Institutes of Health (NIH) signed an open letter on Monday morning to director Dr. Jay Bhattacharya, criticizing the Trump administration over recent moves. The letter, including 92 signed names and 250 anonymous but verified signatories, shares concerns that research is being politicized, global collaboration is being interrupted and that budget and staff cuts have hindered the ability of NIH to do important research. "[W]e dissent to Administration policies that undermine the NIH mission, waste public resources, and harm the health of Americans and people across the globe," the letter reads. "We are compelled to speak up when our leadership prioritizes political momentum over human safety and faithful stewardship of public resources." Some of the NIH scientists who signed the letter, speaking in their personal capacity and not on behalf of the agency, told ABC News they and their colleagues have tried to raise concerns internally -- and repeatedly -- but to no avail. They said there is now an urgency to speak up, especially as Bhattacharya is set to testify on Tuesday at a hearing before the Senate Appropriations Committee on the proposed NIH budget for the upcoming fiscal year. "There is a lot of risk to speaking up, and I am very scared still, even after it's already done, even after it's already said," Jenna Norton, a program officer at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases and one of the lead organizers of the letter, told ABC News. "I think a lot of people are focused on the risk of speaking up, but we also need to think about the risk of not speaking up." The letter, called the Bethesda Declaration -- NIH is headquartered in Bethesda, Maryland -- is modeled after the Great Barrington Declaration, of which Bhattacharya was a co-author. Published in October 2020 and named after the Massachusetts town in which it was drafted, the Great Barrington Declaration called for COVID-19 lockdowns to be avoided and a new plan for handling the pandemic by protecting the most vulnerable individuals but allowing most to resume normal activities, achieving herd immunity naturally. At the time, it was widely criticized by public health professionals, including Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, who said allowing a virus "we don't fully understand to run free is simply unethical." During testimony before Congress in March 2023, Bhattacharya said the declaration was targeted for "suppression" by federal health officials. "We modeled the Bethesda Declaration after the Great Barrington Declaration … because we wanted him to see himself in our action," Norton said. "He's spoken a lot about his commitment to academic freedom and to dissent. If Jay Bhattacharya is the person he very publicly claims to be, and if he is actually in charge at NIH, our hope is that this will move him to action. And if he's not the person he says to be or he's not in charge at NIH, I think the public and Congress should be aware of that." The letter called on Bhattacharya to reverse grants that have been delayed or terminated for "political reasons" and to allow work with foreign collaborators. The signatories also asked Bhattacharya to reverse a policy capping indirect costs for research at 15% and to reinstate essential staff who were fired at NIH. "The Bethesda Declaration has some fundamental misconceptions about the policy directions the NIH has taken in recent months, including the continuing support of the NIH for international collaboration," Bhattacharya said in a statement to ABC News. "Nevertheless, respectful dissent in science is productive. We all want the NIH to succeed." A spokesperson for the Department of Health & Human Services told ABC News that the agency has not halted "legitimate" collaborations with international partners. Additionally, the spokesperson said other funders, like the Gates Foundation, cap indirect costs at 15% and that each case of termination is being reviewed. Ian Morgan, a postdoctoral researcher at the NIH's National Institute of General Medical Sciences whose work focused on antimicrobial resistance, told ABC News seeing the changes at the agency has been a "traumatic experience." He said when the Trump administration came into office, he was prevented from doing research in his lab because he couldn't purchase essential items and he was not allowed to attend a conference in February to speak with potential collaborators. He also saw many of his coworkers get accidentally terminated and then reinstated. "It's just really traumatic and really disruptive for researchers at the NIH," Morgan, who signed the letter, said. "We get into this not because we're trying to make money, not because of our own benefit. We're getting into this because we want to serve the public. We want to do life-saving research." Sarah Kobrin, a branch chief at the NIH's National Cancer Institute (NCI) who also signed the letter, said prior to the new administration, she worked with researchers interested either in receiving funds from NCI or who had funds already and were requesting assistance from NCI. However, with more than 2,100 research grants totaling around $9.5 billion terminated at NIH -- according to the letter -- she said some of her daily tasks have changed. "I spend my time on the phone now talking with people who've just learned that their projects have been cut and have been given false, pseudo-scientific reasons to say their work is not valuable, not important for public health for America, and it's just not true," Kobrin told ABC News. The NIH researchers told ABC News there is a public letter that people can sign to express their support or they can contact their congressional representatives to express their concerns. Morgan, the antimicrobial researcher, said he doesn't want the letter to just be about detailing all the changes that occurred at NIH since Trump took office. "It is us standing up and showing that that not everything is lost, and certainly there's been irreparable damage, but we still have time to right the ship and take it in the right direction," he said. "I need to leave people with that message of hope because, otherwise, they can feel there's nothing that they can do, and that we're powerless, but we are all powerful."
Yahoo
7 hours ago
- Yahoo
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 ( Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective. Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1 Aethlon Medical Inc., San Diego, CA, USA University of California, San Francisco, San Francisco, CA, USA Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Number: 2001Date and Time: August 12, 2025, 1930, MDT. This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc. Sign in to access your portfolio
Yahoo
10 hours ago
- Yahoo
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Poster Presentation Reviews the Hemopurifier® Affinity Resin's Ability to Bind Extracellular Vesicles in Long COVID Samples SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel & Spa, Santa Fe, NM, United States, August 10-13,2025 ( Long COVID refers to persistent symptoms following acute SARs-CoV-2 infection (COVID-19). These symptoms - including fatigue, post-exertional malaise, shortness of breath, chest pain and cognitive difficulties such as "brain fog" - may last for weeks or months after the initial illness. Long COVID is estimated to affect between 44 and 48 million people in the United States alone with a projected economic burden of $2 billion for those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research funding, no treatment has proven effective. Extracellular vesicles (EVs), nanoparticles 50-500nm in diameter, released from all cell types and involved in cell-to-cell communication, have been implicated in the pathogenesis of Long COVID. EVs have been found to contain viral particles and other cargo associated with abnormal blood clotting and inflammation. Aethlon Medical's Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the blood through a combination of plasma separation, size exclusion and binding to a proprietary affinity resin containing the plant lectin Galanthus nivalis agglutinin (GNA), previously found to bind to the sugar mannose. The Hemopurifier has previously been shown to remove EVs in a patient with severe acute COVID-19 infection. Aethlon Medical collaborated with the University of California San Francisco Medical Center Long COVID clinic to evaluate plasma samples from participants with Long COVID and control participants who had fully recovered from COVID-19 in order to examine whether individuals with Long COVID would have EVs with the mannose target on their surface that would bind to the affinity resin in the device. The data to be presented will review the binding of both larger and smaller EVs to GNA lectin and the lectin-based affinity resin, respectively. Presentation details and times are as follows: Title: Extracellular Vesicles from Participants with Long COVID are Mannosylated and Bind to the Galanthus Nivalis Agglutinin Resin in the Aethlon Hemopurifier® Authors: Miguel Pesqueira1, Rosalia de Necochea Campion1, Thomas Dalhuisen2, Emily A. Fehrman2, Jeffrey N. Martin2, Timothy J. Henrich2, Steven G. Deeks2, Michael J. Peluso2, Steven P. LaRosa1 Aethlon Medical Inc., San Diego, CA, USA University of California, San Francisco, San Francisco, CA, USA Presenter: Steven P. LaRosa, M.D, Chief Medical Officer, Aethlon Medical, Number: 2001Date and Time: August 12, 2025, 1930, MDT. This poster will be available following the meeting on the Aethlon Medical, Inc. corporate website at About Aethlon and the Hemopurifier® Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation, and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies. Additional information can be found at Company Contact:Jim FrakesChief Executive Officer and Chief Financial OfficerAethlon Medical, Inc. Jfrakes@ Investor Contact:Susan NoonanS.A. Noonan Communications, LLCsusan@ View original content: SOURCE Aethlon Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data